Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML

NCT01690065 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
46
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ulsan University Hospital

Collaborators